All In Biotech

Drug Trial Radar · NCT06782334

AMT-116 in Patients with Solid Tumors

Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

May 7, 2024

Primary completion

Jun 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Multitude Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Conditions

  • Advanced Solid Tumors

Interventions

  • AMT-116Drug

    AMT-116 is an antibody Drug Conjugate (ADC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Maximum Tolerated Dose(MTD) and the Recommended Phase 2 Dose(RP2D) of AMT-116Time frame: approximately 12 months
  2. Phase I: Type, incidence and severity of Adverse Events,Dose Limiting Toxicities (DLTs)Time frame: approximately 12 months
  3. Phase II: Objective Response Rate(ORR)Time frame: approximately 18 months
  4. Phase II: Type, incidence and severity of Adverse EventsTime frame: approximately 18 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Not yet recruiting

  • Zhujiang Hospital of Southern Medical University(The Second Clinical Medical College)

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Zhejiang cancer hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.